A Silent Killer Lurks in Newborns, But This Protein Might Hold the Key. Early-onset sepsis (EOS), a devastating bloodstream infection striking within days of birth, claims countless infant lives globally. While symptoms like poor feeding and lethargy are vague, doctors often turn to C-reactive protein (CRP) as a potential early warning sign. But is CRP the reliable hero we need in this battle? And this is the part most people miss: its accuracy isn't one-size-fits-all. A groundbreaking study led by Professor Hugh Simon Lam from The Chinese University of Hong Kong sheds new light on CRP's potential and limitations. Published in Pediatric Investigation (October 24, 2025), this research delves into the complex relationship between CRP levels and EOS risk, particularly in preterm infants.
Analyzing data from over 100,000 newborns in Hong Kong, the team discovered a crucial nuance: CRP levels naturally rise in healthy babies after birth, peaking around 24-32 hours. This physiological surge, more pronounced in term babies, can mask true infections. Here's where it gets controversial: while CRP proved highly accurate in identifying EOS in preterm babies (CRP > 8.0 mg/L after 4 hours), its performance in term infants was lackluster, leading to potential missed diagnoses and unnecessary antibiotic use.
The study also explored CRP's role in predicting early-onset meningitis, a rare but deadly complication. A CRP level above 12.0 mg/L emerged as a strong indicator, offering hope for earlier intervention. However, the research underscores the need for context-aware interpretation. Gestational age, postnatal age, and other factors must be considered alongside CRP results to avoid misdiagnosis.
Professor Lam emphasizes, “While CRP isn’t a perfect biomarker for EOS, it remains a valuable tool, especially for preterm infants. It helps assess infection risk and guides further testing for meningitis.”
This study highlights the complexities of neonatal sepsis diagnosis. CRP, though not a silver bullet, offers a cost-effective and accessible screening method when used judiciously. But the question remains: how can we further refine our diagnostic arsenal to protect these vulnerable newborns?
What are your thoughts? Should CRP be used more selectively, focusing on preterm infants? How can we balance the need for early detection with the risks of over-treatment? Let’s continue the conversation in the comments.
